Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

PHASE3RecruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
BCLC Stage C Hepatocellular CarcinomaChemotherapy Effect
Interventions
DRUG

intravenous FOLFOX7 plus Camrelizumab and apatinib

"Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg,po,qd for every 21 days"

DRUG

HAIC-FOLFOX plus Camrelizumab and apatinib

"2-h infusion of oxaliplatin at 85 mg/m2 ,a 2-3-h administration of leucovorin at 400 mg/m2 , and a 46-h delivery of fluorouracil at 2500 mg/m2.~camrelizumab (200 mg intravenously, commencing in 7 days after the first HAIC cycle and repeated every 21 days) and apatinib (250 mg daily, taken orally, beginning in 7 days after the initial HAIC cycle) Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg,po,qd for every 21 days"

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER